GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Meribank Biotech Co Ltd (ROCO:4724) » Definitions » Capex-to-Operating-Income

Meribank Biotech Co (ROCO:4724) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Meribank Biotech Co Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Meribank Biotech Co's Capital Expenditure for the six months ended in Dec. 2023 was NT$-1.01 Mil. Its Operating Income for the six months ended in Dec. 2023 was NT$-63.68 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Meribank Biotech Co Capex-to-Operating-Income Historical Data

The historical data trend for Meribank Biotech Co's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Meribank Biotech Co Capex-to-Operating-Income Chart

Meribank Biotech Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial - - - - -

Meribank Biotech Co Semi-Annual Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Meribank Biotech Co's Capex-to-Operating-Income

For the Biotechnology subindustry, Meribank Biotech Co's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Meribank Biotech Co's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Meribank Biotech Co's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Meribank Biotech Co's Capex-to-Operating-Income falls into.



Meribank Biotech Co Capex-to-Operating-Income Calculation

Meribank Biotech Co's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-6.678) / -118.514
=N/A

Meribank Biotech Co's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-1.009) / -63.675
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Meribank Biotech Co  (ROCO:4724) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Meribank Biotech Co Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Meribank Biotech Co's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Meribank Biotech Co (ROCO:4724) Business Description

Traded in Other Exchanges
N/A
Address
Sector 1, Neihu Road, 1st Floor, No.68, Neihu District, Taipei, TWN, 11493
Meribank Biotech Co Ltd is engaged in Research and development and sales of new cell drugs and also Umbilical cord blood, placenta and umbilical cord mesenchymal stem cells processing, testing and cryopreservation.

Meribank Biotech Co (ROCO:4724) Headlines

No Headlines